Clinical Trials Logo

Uveal Melanoma clinical trials

View clinical trials related to Uveal Melanoma.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04577742 Completed - Uveal Melanoma Clinical Trials

Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Start date: February 1, 2011
Phase:
Study type: Observational

This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

NCT ID: NCT04551352 Completed - Uveal Melanoma Clinical Trials

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Start date: October 28, 2020
Phase: Phase 1
Study type: Interventional

This is a first-in-human, multi-center clinical study to determine the safety, Maximum Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or are non-amenable to SOC. This study will include an initial single participant dose-escalation part one followed by a multiple participant dose-escalation part two with the possibility of expansion.

NCT ID: NCT03922880 Completed - Uveal Melanoma Clinical Trials

Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma

Start date: April 16, 2019
Phase: Phase 1
Study type: Interventional

This study is measuring the safety of the study drug, ADI-PEG 20, combined with immunotherapy drugs nivolumab and ipilimumab in treating patients with advanced uveal melanoma.

NCT ID: NCT03712904 Completed - Uveal Melanoma Clinical Trials

Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma

Start date: August 9, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well stereotactic body radiation therapy and aflibercept work in treating patients with uveal melanoma. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving stereotactic body radiation therapy followed by aflibercept may work better in treating patients with uveal melanoma.

NCT ID: NCT03652077 Completed - Ovarian Cancer Clinical Trials

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Start date: September 24, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

NCT ID: NCT03408587 Completed - Liver Metastases Clinical Trials

CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)

CLEVER
Start date: January 29, 2018
Phase: Phase 1
Study type: Interventional

This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.

NCT ID: NCT03297424 Completed - Solid Tumor Clinical Trials

A Study of PLX2853 in Advanced Malignancies.

Start date: September 12, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

NCT ID: NCT03207347 Completed - Clinical trials for Renal Cell Carcinoma

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Start date: August 13, 2018
Phase: Phase 2
Study type: Interventional

This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.

NCT ID: NCT03052127 Completed - Uveal Melanoma Clinical Trials

Study in Subjects With Small Primary Choroidal Melanoma

Start date: February 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

NCT ID: NCT02849145 Completed - Uveal Melanoma Clinical Trials

Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)

Start date: September 2014
Phase: N/A
Study type: Interventional

Prospective, open labelled, monocentric trial to evaluation of the circulating tumor DNA rate in the blood, before and after curative resection of hepatic metastasis of uveal melanoma (HMUM) and during post-surgery follow-up